Alliance Pharma to acquire LGC’s Drug Development Solutions business, with KKR as joint shareholder

Alliance Pharma (PA, USA), a bioanalytical CRO, has agreed to acquire Drug Development Solutions (DDS), a bioanalytical business unit of LGC (Cambridge, UK).

Alliance Pharma (PA, USA), a bioanalytical CRO and one of Ampersand’s portfolio companies, has agreed to acquire LGC’s Drug Development Solutions (DDS) business (Cambridge, UK), with KKR (NY, USA) agreeing to become an equal shareholder alongside Ampersand Capital Partners (MA, USA). Backed by these two major companies, Alliance and DDS are strategizing to broaden the company’s laboratory capabilities, to increase its service portfolio and widen the company’s geographical reach. All transactions, subject to regulatory approvals, are expected to be finalized by Q2 2022.

Eric B. Lev, General Partner at Ampersand Capital Partners, and Kugan Sathiyanandarajah, Managing Director at KKR, commented:

“Alliance and DDS are highly complementary businesses with industry leading management and scientific teams, and strong track records of supporting leading pharma and biopharma customers. We are delighted to be collaborating to bring together two well respected and fast-growing bioanalytical lab services businesses to create one of the leading global specialty bioanalysis platforms.”

You may be interested in:

• Newomics Inc. announces its collaboration with Bruker Corporation on high-throughput bioanalysis
• Technology Digest: implementation of automation, IT support and cybersecurity in bioanalysis
• In the Zone: flow cytometry for cell and gene therapies

The combined companies will benefit customers as they will have access to international capabilities in newly emerging areas of bioanalytical science such as cell and gene therapy.

Euan O’Sullivan, President and CEO of LGC, concluded:

“I am proud of the scientific and commercial achievements delivered by the DDS business over the years, supporting customers in their mission to develop new medicines and products to improve the quality of life. I am confident that as part of the Alliance organization, the DDS team will be well positioned for on-going success as part of a global business focused on bioanalytical and materials sciences activities.”

Source: LGC press release: www.lgcgroup.com/newsroom-and-blog/news-and-blog/alliance-acquires-lgc-dds/